Delivered-To: pgepnewsletter@gmail.com
Received: by 2002:a98:d84b:0:b0:1eb:e128:bbe3 with SMTP id b11csp1287870eil;
        Fri, 19 Jan 2024 17:56:18 -0800 (PST)
X-Google-Smtp-Source: AGHT+IFmHynAWK+O3LGkGtZN+ykvuxR6YGZLCRwi3DsubK5RDeP2bqiayBdxda58U4XXJXght1w3
X-Received: by 2002:a05:6214:2623:b0:681:80b8:72a with SMTP id gv3-20020a056214262300b0068180b8072amr844465qvb.87.1705715778369;
        Fri, 19 Jan 2024 17:56:18 -0800 (PST)
ARC-Seal: i=1; a=rsa-sha256; t=1705715778; cv=none;
        d=google.com; s=arc-20160816;
        b=Ht5YXH3naI7d8C5aXQkIxEsEiIApXjvWcYEj5s0LTdRHauhWFzAVKrGtrtp0kmkRcN
         bRTkcV4FkQT/jfLuYP90XapJCE9M4u5uLLaTVwmGHfPW+6YwuX3MPKuQZYJbJLVSIXB2
         msNsfdRnBKi3yQMmbrMr0RhIJvzR//FC1Y+3M8ioedgBDfTu538za2T3K4sYV2VveJWW
         MCou3J3BQcHTA/XzY+drCTLPUeFeSDSGLFNzX0SVMlVSyOrP8Vzmjub8MTgLF/ifZNKq
         Lv/eVrzJhKohhLICkp8sKWB0Xje6EomkkE2V//l2BPgfzfTdydgPCxDGNcS/J6I6mthB
         J6wg==
ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20160816;
        h=list-unsubscribe:to:reply-to:subject:message-id:mime-version:from
         :date:dkim-signature:dkim-signature;
        bh=mP9us38vm+GyxuFKDDL/SpI06C3+z6V1UuhPyXPgLN8=;
        fh=m8+yFGL9AGrkSifADXzxzWHypeMVd9MF7/kbikeN2H4=;
        b=vGTfkJWVJMOm2YtEk031GbVLxgswhAk629dG/S0TItmtSfefocAepxJxNuwZ+34XKL
         sFyheF0TXQFRDdJP/MGnXWG2ktHUERMBfH5CcJXjXhfpRHf1xvjj2Sm56GCT4dqrBaeV
         Tc0hDbLpUvRsX1kgDbGxCPgoONb8bh/w3yQXAlPpTIpeCeYdsLqhCn+dTILR4vcH0sPt
         4RhB22ZRR/IyOKU4pz2Ambt6FS0yMlPTuvBlwYT3EWpbxE3DgZ5n1vNEITAEJLEMot4Z
         LtYBG/ibDh0kbdSjPLzu3eZSbxwmHBU5VdASqd5QA0z8sX9L0XjRjmFsjXgtiXqV/4o4
         IYug==
ARC-Authentication-Results: i=1; mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=mw7Bmm1v;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=Jl9rkHCu;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
Return-Path: <bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org>
Received: from xtrwrkzn.outbound-mail.sendgrid.net (xtrwrkzn.outbound-mail.sendgrid.net. [167.89.81.226])
        by mx.google.com with ESMTPS id q2-20020a0ce202000000b0067f584b65besi591319qvl.263.2024.01.19.17.56.18
        for <pgepnewsletter@gmail.com>
        (version=TLS1_3 cipher=TLS_AES_128_GCM_SHA256 bits=128/128);
        Fri, 19 Jan 2024 17:56:18 -0800 (PST)
Received-SPF: pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) client-ip=167.89.81.226;
Authentication-Results: mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=mw7Bmm1v;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=Jl9rkHCu;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=isid.org;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=s1; bh=mP9us38vm+GyxuFKDDL/SpI06C3+z6V1UuhPyXPgLN8=;
	b=mw7Bmm1vETRUiONx9CX77RW3esEoqTgHAfnF5gGTMQMR1ziCi89jr54fWEJT0lqrayPP
	Yyc+NRLKpkp8y2c5Qkj3qbj1jm8lUsTxkN6CSAQMIQYAcAmwkPFSUtRnNnqdoNNGM8a4+t
	UUzy3TpFX8PREUoGK/+PulpBKTHGg3XiJ8bGsVWN1I0ZD9q0CAFixCmpOadG59J/OO5fyI
	mod93SOGsEVJmmLHijSQueEygzCCdQDpr5+zXV1p5P6fTKe9tqJcYfNHmHnyZKZXCuYx3E
	rdogADcp0DRgxyfl7Ca8BB443KYvbBErnmdv9nCzzKxLO1qxPcjT7r+N72bBUuuQ==
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=sendgrid.info;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=smtpapi; bh=mP9us38vm+GyxuFKDDL/SpI06C3+z6V1UuhPyXPgLN8=;
	b=Jl9rkHCumuADu7fIYm/W3RJQCPJNFN41VKjZb9wZPhBfRrjqKHBPWQnFiG5LnTR9GvF1
	LAP47vOABh0X7K4BMHaIPK+PX3Ho9LZ4CjgWa6Vg4JV0QqZ9wSLdlCdK6Moi9c7Hk7c7gM
	3hLlOH2POmmO5mUeIZ0YETt44k/5cP+Y4=
Received: by filterdrecv-647c69fd5c-8f2t7 with SMTP id filterdrecv-647c69fd5c-8f2t7-1-65AB2840-C
        2024-01-20 01:56:16.200103862 +0000 UTC m=+8147649.455215175
Received: from MTkyNjg2NjI (unknown)
	by geopod-ismtpd-6 (SG) with HTTP
	id iqN8qe5ASHy_cGbV2MIEdg
	Sat, 20 Jan 2024 01:56:16.175 +0000 (UTC)
Content-Type: multipart/alternative; boundary=f56ebc30e08713cc66201f46902592c9ace2e4c4a4088ccd62999e81c428
Date: Sat, 20 Jan 2024 01:56:18 +0000 (UTC)
From: ProMED <promed@isid.org>
Mime-Version: 1.0
Message-ID: <iqN8qe5ASHy_cGbV2MIEdg@geopod-ismtpd-6>
Subject: PRO/EDR> Diphtheria - Nigeria
Reply-To: noreply@isid.org
X-Feedback-ID: 19268662:SG
X-SG-EID: 
 =?us-ascii?Q?lYKUi1ucKQwcfoVB1xAcbBSlsJP9QSi7ed2VWI0p5NjpCc5BQK+kujBGGO1mU1?=
 =?us-ascii?Q?iBnK8ROyPrj=2F8uI+YvVP93Sv37q6hvUh1K8zLl1?=
 =?us-ascii?Q?JB=2F1S1y1NIAzDX3Ht6N5Ubp+9k5pUO6LeAL4ZQi?=
 =?us-ascii?Q?GZKflBTp=2F=2Fx801tFFW6U=2FLAgDMiJw+lBFpaDDxE?=
 =?us-ascii?Q?xyxOqAI+W5yj515m27vEa8R5zKCFVvKpK+Sc2I7?=
 =?us-ascii?Q?D4r5MNDyAKlzvzqosmFo5UqOO2rY9dEKcxDHB5?=
X-SG-ID: 
 =?us-ascii?Q?se=2F49CGmbS0sfR97ImeXvNhg9p9jggtUUChgqoY2wUhc93xcG=2F095a5S4+mt=2FG?=
 =?us-ascii?Q?uYUpctI=2FOGD2dwyi+uvm2j4FCdvuw0l9zcHM8iA?=
 =?us-ascii?Q?mojOvTXq7jOpDFFNtfsYkHQYACEW8pq1BXXqYmH?=
 =?us-ascii?Q?oGTsnt6QpE2ZV5WVqnpwfXWoLXx7+4ZTIIDaarg?=
 =?us-ascii?Q?KWj9hWnKDkUuOcNFUmIeM3vdzC1hYVz+iFODw5M?=
 =?us-ascii?Q?psOVBb1p8WR9OMq3swvC8xDV2ZHhYgzlexh=2FzSK?=
 =?us-ascii?Q?ZNmqM=2FJ8w3Yur6JD7yDCbuZ9UHL5xCfIuk+l95N?=
 =?us-ascii?Q?JcchMGdakTOWwfzJoITBIbL6+UL32ghHnGPXxtO?=
 =?us-ascii?Q?fkf9u7vrbSrIGXKq2fCIzSlxkmoEF1mer5=2F70YH?=
 =?us-ascii?Q?TrAhco37KgzSKO34jhF+XCuen8a2+u4swjkU9qw?=
 =?us-ascii?Q?v5O1bPCQAZlHVVKlTWBO=2FfoxQagXHTGmnzV1eAD?=
 =?us-ascii?Q?AS18TVoIiB1wHKwM0lNzhMowTvKJX6E9SeeV8Mh?=
 =?us-ascii?Q?cm7No6yTWsnuT4SrcfKEwLNTbpe9Jlf5uu23+FV?=
 =?us-ascii?Q?rjGJ3b9fDLMGYlMHma1V0+PaVGXc8ORgXnnhul5?=
 =?us-ascii?Q?o5wqEg2oQfOgYItMGHM2upz45TaDVVEu4PimzVc?=
 =?us-ascii?Q?=2FlmeFrbF2fhJFEIlWj8or+BjmvwqThIqD9RaKsm?=
 =?us-ascii?Q?RPlZ8xAE8CTUsAltFApoidGnmRjcuklNxx54d=2Fr?=
 =?us-ascii?Q?=2FkY83OHr9yibDry=2FRkjoiJOLRJV3Ph0MOmu+143?=
 =?us-ascii?Q?cYOm=2FceaESUcL83hvPAJaHyMtuLr+SBLE17u14k?= =?us-ascii?Q?EDCK?=
To: pgepnewsletter@gmail.com
X-Entity-ID: 3CKJgmVGbBVD214dsRqreg==
List-Unsubscribe: 
 =?us-ascii?Q?=3Cmailto=3Aunsubscribe=40em7004=2Eisid=2Eorg=3Fsubject=3D19268662=2ESMn2ixUW3?=
 =?us-ascii?Q?HSvu-PiD6IxESA3PD=5FMabyaow8Pf2YSQiRoMDAw?=
 =?us-ascii?Q?dTAwMO-fL0z3=5F-bm3D06QazAEMF4eQK=5F4lwIPB9?=
 =?us-ascii?Q?HFmmwzJ6uXl=5FJ83ErrDqfF9PNJNL46tNj25wWfm?=
 =?us-ascii?Q?K=5FsH4Oa4JK4lzOHWYWoLnYVdcmLAK=5Fpeg4NT-1X?=
 =?us-ascii?Q?8iDkvCJOi8AdHBNbQ=3D=3D=2E92iW5A9RwtwiRmeB99A?=
 =?us-ascii?Q?hjYuyzG-587IDgiRgDcAc1R1oMDAwdTAwMBxRaj?=
 =?us-ascii?Q?BSA=5FP-28RuHK379SRX4cX3ykQAX7wQH2jPcfxnT?=
 =?us-ascii?Q?Ogm8aIajMnc=5FjeKG2opsHY8YuW0Jtabvf6sIMcb?=
 =?us-ascii?Q?y0nX3sQT9jBsiDY=5FH93ktf4KUauAOyBugcQzYPB?=
 =?us-ascii?Q?P-9ZRLh88ZPKpOZoSHIdy425fZqk3yIjGkDoFOx?=
 =?us-ascii?Q?yeK42EesI3n31B=5Fmfg1qUOKJQMciLgcN7dhbj8h?=
 =?us-ascii?Q?Ei4PQagKfSKIkCsUT9z9pKCwR073Af6JBX82AJ-?=
 =?us-ascii?Q?3Sv-efPp1R14UJ1sNJXAOmcw=5FhawNAuZs-dDSZK?=
 =?us-ascii?Q?L7KvBuZt=5F9=5Fx28YSkDmtEhOlIxqKrmQYbKS5TER?=
 =?us-ascii?Q?k-48lQ-reyjB8Kz2fkXbC0jxZ9G-7ELRvlo0jsa?=
 =?us-ascii?Q?6MD4dqR4rdW0x=5F-57hmd48p8kOVMwbueLr6KIDo?=
 =?us-ascii?Q?DsJ6GhKLHAwP=5FNLvtHiwo9iGF6R58DS0LYZCgIt?=
 =?us-ascii?Q?nZPqvI2YIGAwNhXJnf88n8x94r9MTxc2Q62GISG?=
 =?us-ascii?Q?7hBchK9tJt1O4=5FM7chw6x3jeMcF=5Fwl9HT=5Fxq2Y=5F?=
 =?us-ascii?Q?RE-Al4ubeoWIf8OJM6lwBbNIMpxjAKfVqrnfsgu?=
 =?us-ascii?Q?UWpxw6MU20S5N82kzifVczSDymK5nX6y377MyH9?=
 =?us-ascii?Q?8An=5FXj04kxuh02z57i72VjQSYw7zsjxKcxyxofZ?=
 =?us-ascii?Q?lZhfx8YkYQzN1Z32x8xyPIGoujgwLGkv5xG8Nhi?=
 =?us-ascii?Q?w-KxA9e3Kl=5FDPzc6PcDopK-vzGvjNoBRaPBFZCN?=
 =?us-ascii?Q?FQfGJMcpmTKKPhYHI7xr4u3TN5i=5FyYnVi1TMRbP?=
 =?us-ascii?Q?RBiGlY9Q4sjnpCEIkoEwgogKuEOQBNRh8Fu6FQm?=
 =?us-ascii?Q?oqSk2FuAJSpV38OpP7W50EjSo4ivjoMONQ1omWK?=
 =?us-ascii?Q?UsyWrS5=5FD=5FJIU-Ewi5BREeAS-kcZldmhGxybCJY?=
 =?us-ascii?Q?f6qwN80U3BgU69ZsFHCbVnFfMOgUWYyWpRF6zxo?=
 =?us-ascii?Q?b98mySmr36adTeWS90TEIphmxPFUU9oyTq4nARs?=
 =?us-ascii?Q?6TgITxb0WvVHua4g8KuSQSW4UyCxyP876OS6yLa?=
 =?us-ascii?Q?cgAqBwwFN8lPd0eZJpieaYP=3E?=

--f56ebc30e08713cc66201f46902592c9ace2e4c4a4088ccd62999e81c428
Content-Transfer-Encoding: quoted-printable
Content-Type: text/plain; charset=us-ascii
Mime-Version: 1.0

DIPHTHERIA - NIGERIA
********************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Wed 17 Jan 2024
Source: IFRC [edited]
<https://reliefweb.int/report/nigeria/nigeria-diphtheria-outbreak-operation=
-update-2-mdrng037-0>


Nigeria | Diphtheria Outbreak - Operation Update 2 (MDRNG037)
-------------------------------------------------------------
A. Situation Analysis
---------------------
Description of the crisis

In Nigeria, the outbreak of diphtheria became the biggest public
health concern that affected many lives and children in 2023. This
outbreak began in Kano State in December 2022 and spread to
neighboring states, including Lagos and Osun, which have reported
confirmed cases. The NCDC has declared this outbreak to be the worst
in a decade, with the previous outbreak occurring in 2011 in Nigeria.
As of December 2023, over 13 000 confirmed cases have already been
reported across approximately 20 states with majority of people
affected being children.=20

Diphtheria is a vaccine preventable disease and severe bacterial
infection that can affect a person's nose, throat, and occasionally
skin. It is brought on by some toxin-producing species of the
bacterium _Corynebacterium_. The people at the greatest risk of
contracting diphtheria are among children and people who have not
received any, or only a single dose of the vaccine (a diphtheria
toxoid-containing vaccine). People at risk are communities residing in
densely crowded places and unsanitary areas with poor environmental
conditions. Also, healthcare professionals and hospital frontline
workers who are working with or in close contact with people suffering
from diphtheria are at risk of contracting the disease. There is also
a risk of contracting diphtheria if a person comes physically into
contact with someone with diphtheria.

[The full report can be found at the above URL. - Mod.LL]

--
Communicated by:
ProMED

[The following article is a good review of diphtheria:
Sharma NC, Efstratiou A, Mokrousov I, Mutreja A, Das B, Ramamurthy T.
Diphtheria. Nat Rev Dis Primers. 2019 Dec 5;5(1):81. doi:
10.1038/s41572-019-0131-y.
---------------------------------------------------------------------------=
-----
Abstract
--------
"Diphtheria is a potentially fatal infection mostly caused by
toxigenic _Corynebacterium diphtheriae_ strains and occasionally by
toxigenic _C. ulcerans_ and _C. pseudotuberculosis_ strains.
Diphtheria is generally an acute respiratory infection, characterized
by the formation of a pseudomembrane in the throat, but cutaneous
infections are possible. Systemic effects, such as myocarditis and
neuropathy, which are associated with increased fatality risk, are due
to diphtheria toxin, an exotoxin produced by the pathogen that
inhibits protein synthesis and causes cell death. Clinical diagnosis
is confirmed by the isolation and identification of the causative
_Corynebacterium_ spp., usually by bacterial culture followed by
enzymatic and toxin detection tests. Diphtheria can be treated with
the timely administration of diphtheria antitoxin and antimicrobial
therapy. Although effective vaccines are available, this disease has
the potential to re-emerge in countries where the recommended
vaccination programs are not sustained, and increasing proportions of
adults are becoming susceptible to diphtheria. Thousands of diphtheria
cases are still reported annually from several countries in Asia and
Africa, along with many outbreaks. Changes in the epidemiology of
diphtheria have been reported worldwide. The prevalence of toxigenic
_Corynebacterium_ spp. highlights the need for proper clinical and
epidemiological investigations to quickly identify and treat affected
individuals, along with public health measures to prevent and contain
the spread of this disease."

This infection is vaccine preventable in countries that have a public
health system to deliver the appropriate immunogen. The toxoid for
diphtheria prevention is now generally combined with toxoids to
prevent tetanus and sometime pertussis. Historically, the original
killed whole cell pertussis vaccine was licensed in 1914. The same
year, the mixtures of diphtheria toxin and antitoxin were put into
use. In 1926, alum-precipitated diphtheria toxoid was registered, and
in 1937 adsorbed tetanus toxoid was put on the market. Pertussis
vaccine is now an acellullar toxoid product. - Mod.LL

ProMED map:
Nigeria: <https://promedmail.org/promed-post?place=3D8714345,62>]

[See Also:
2023
----
Diphtheria - France: ex West Africa, multidrug resistance
http://promedmail.org/post/20231117.8713196
Diphtheria - Asia, Africa: Pakistan (KP) South Africa (WC) fatal,
prison http://promedmail.org/post/20231111.8713097
Diphtheria - SE Asia (06): India (HR) fatal
http://promedmail.org/post/20231025.8712821
Diphtheria - SE Asia (04): Indonesia (JR) fatal
http://promedmail.org/post/20230807.8711603
Diphtheria - SE Asia (03): Indonesia (JI)
http://promedmail.org/post/20230709.8711048
Diphtheria - South Africa: (NL, WC) antitoxin shortage
http://promedmail.org/post/20230519.8710144
Diphtheria - SE Asia (02): Indonesia (JR) fatal, more cases, vaccine
campaign, RFI http://promedmail.org/post/20230319.8709034
Diphtheria - SE Asia: Indonesia, fatal, more cases, vaccine campaign,
alert http://promedmail.org/post/20230222.8708538
2022
----
Diphtheria - France: migrants, toxigenic Corynebacterium
diphtheriae/C. ulcerans http://promedmail.org/post/20221230.8707531
Diphtheria - Australia: (NSW) unvaccinated children
http://promedmail.org/post/20220705.8704239
2018
----
Diphtheria - Philippines: increased cases, 4 regions
http://promedmail.org/post/20181215.6210623
Diphtheria - Indonesia: fatal, more cases, vaccine campaign
http://promedmail.org/post/20180106.5542510]
.................................................ll/may/jh
*##########################################################*
************************************************************
ProMED makes every effort to verify the reports that are posted, but the ac=
curacy
and completeness of the information, and of any statements or opinions base=
d
thereon, are not guaranteed. The reader assumes all risks in using informat=
ion
posted or archived by ProMED. ISID and its associated service providers sha=
ll not
be held responsible for errors or omissions or held liable for any damages =
incurred
as a result of use or reliance upon posted or archived material.
************************************************************
Donate to ProMED. Details available at: https://isid.networkforgood.com/pro=
jects/79924-invest-in-the-mission.
************************************************************
Visit ProMED's website at https://www.promedmail.org/.
Submit all items for posting via the ProMED website at https://promedmail.o=
rg/submitinfo/.
If you have any questions or need support, please contact us via the ProMED=
 website at  https://promedmail.org/support/.
You may subscribe/unsubscribe at  https://isid.org/promedmail-subscribe/.
Unsubscribe Preferences ( https://u19268662.ct.sendgrid.net/asm/?user_id=3D=
19268662&data=3DNwnq9EpY-X5H7PaTmZxXTkYD4qeihjh30Myiq9yDK0hoMDAwdTAwMLLcgGC=
cfF0v9Fa2Ji6PFlm_MGEPUiVhIN37PmRW3q3PtWyOT10GRHBaf_kbDWaQBg4CI0Dt0o3fieBIOJ=
5Dr17RetC6i2F8IZ3J7-WnzEBjSdRYZRcUhHTNFojdrTIUrylzAEQxGXtvjuCh7YSG83-xUqQ3v=
yJf8mKCUQZ8cqTsOliSdbVv_wz1Yta7j-6pujigBEB-DdtChkX6C1cjSsb1U8IBmLZKsKzdYRXC=
7UjN-xdqO29JrRyWcTKpPK7TWm809egmxI1KOwieua5TT_SfS2n3RmtqwlWUPR2csIqmDw4a7Fk=
DPpUMrT31egtyUU-v5UrVBSIsX0Sbj_8r79eXOgKpZAQyBlTMf5BPKMFFY2QvFv_100Jblrvb8N=
ku0CWAdw7EXPA90wDd9GYJtc9B87bpFSIGNK2k1zWeDTPhp3tA1YRb-406S-3yp7lgX02uvnj6z=
ztDVf5hdTSUMXKOnfR1fJ46FnIe-F4CWa9pTCWGEo9XBJuXzMnZ65Nb53vuayQMxlbqdoyduQTE=
V6b4hXQh1yATAhNQ9sBq3VjV_gafy4Qe7GeHVX1VBA5uhG3lJTAxEht6xqSgomqmbGDrGG6Ky6a=
q3ONjIMVVHDk0muTV22X5SwB9sVSx9hY58lXGF3zlplBU-zI5jvjY-xqo7ORXV9gMRqRVCaff3F=
2i1sghOVX2u6O2fOnGYLmR1oqWJBlBts6G4YY7TQZrFnkl9cEWyuy__DKZktpVixd4D-o2_jNSE=
vYWk9RyXWHNVXasbHElSjrqJeoh811bwVCxYiOvNqlRBET_Se-0TCTg4DvXLQN7aAYLRbt5SCAl=
Tj8AsiGSVo2--T0vgRpOVOxlfoQzinolSWv7KBkc0M9_nCqCTLKCn0JT92veDmiPzTiEorngQp4=
gBlsmxWuQNmzzbTXVHi9z7wyMq4E6L--vLBlHRa6h8Joim2X7fityc4Oc_xye0Xh4FQWuHHkjBZ=
7HSwz1Ic36QYEYDYD7T8CpycsMnF-B6FcfYbZTanscvyG150zzjgyl2eiGUVt_nOag-xEoS85PG=
0n_Ob0AyDx6qyQM-AarFIjxFTPxMfwM04psQbOauJrpVXQggUKBgNQJa4Wh70cdZ_oKa_NjfCAm=
BRTeevGNerQVEp3SW4LB1A=3D=3D )
############################################################
############################################################

--f56ebc30e08713cc66201f46902592c9ace2e4c4a4088ccd62999e81c428
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset=us-ascii
Mime-Version: 1.0

<!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>DIPHTHERIA - NIGERIA<br>********************<br>A ProMED-mail post<br=
><a href=3D"https://u19268662.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisIij=
pefK5PNjW-mL-YZGnfgDOxU1G3gjwnPSi2Tfv3HA/435/tY0QTiX0ReqDHo3w_m7uOQ/h0/i-Li=
VT70L-N5cvh86gD9COeBUuu4Wvq9SoqvybaeORY">http://www.promedmail.org</a><br>P=
roMED-mail is a program of the<br>International Society for Infectious Dise=
ases<br><a href=3D"https://u19268662.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt4=
8tisCT5tpD4Upm3qyMCbcYSQvc/435/tY0QTiX0ReqDHo3w_m7uOQ/h1/Tp-XVvVAZdg25E-PJ6=
Gn25diuiyM6TdAM3U-9s6oqxY">http://www.isid.org</a><br><br>Date: Wed 17 Jan =
2024=0D<br>Source: IFRC [edited]=0D<br><a href=3D"https://u19268662.ct.send=
grid.net/ss/c/suRyKAAhd_WyEaNz14Vl-qVBgHNzQ_3sSOh4iwJY841cx8sCsf-lWUHm6NvH5=
l721hTYsgpa8IjXGsVkLZUrfgl2xuuZBJqpdP3dyaV-M7GRpPNOee_2sIfFQuM1CEIpH1ZR8mjy=
fV8RqO6BTeY2WA/435/tY0QTiX0ReqDHo3w_m7uOQ/h2/6U5oheoojWJj9BAS7-RVhtQx1DRkhQ=
sQeCa3barBBkg">https://reliefweb.int/report/nigeria/nigeria-diphtheria-outb=
reak-operation-update-2-mdrng037-0</a>=0D<br>=0D<br>=0D<br>Nigeria | Diphth=
eria Outbreak - Operation Update 2 (MDRNG037)=0D<br>-----------------------=
--------------------------------------=0D<br>A. Situation Analysis=0D<br>--=
-------------------=0D<br>Description of the crisis=0D<br>=0D<br>In Nigeria=
, the outbreak of diphtheria became the biggest public<br>health concern th=
at affected many lives and children in 2023. This<br>outbreak began in Kano=
 State in December 2022 and spread to<br>neighboring states, including Lago=
s and Osun, which have reported<br>confirmed cases. The NCDC has declared t=
his outbreak to be the worst<br>in a decade, with the previous outbreak occ=
urring in 2011 in Nigeria.<br>As of December 2023, over 13 000 confirmed ca=
ses have already been<br>reported across approximately 20 states with major=
ity of people<br>affected being children.=20=0D<br>=0D<br>Diphtheria is a v=
accine preventable disease and severe bacterial<br>infection that can affec=
t a person's nose, throat, and occasionally<br>skin. It is brought on by so=
me toxin-producing species of the<br>bacterium _Corynebacterium_. The peopl=
e at the greatest risk of<br>contracting diphtheria are among children and =
people who have not<br>received any, or only a single dose of the vaccine (=
a diphtheria<br>toxoid-containing vaccine). People at risk are communities =
residing in<br>densely crowded places and unsanitary areas with poor enviro=
nmental<br>conditions. Also, healthcare professionals and hospital frontlin=
e<br>workers who are working with or in close contact with people suffering=
<br>from diphtheria are at risk of contracting the disease. There is also<b=
r>a risk of contracting diphtheria if a person comes physically into<br>con=
tact with someone with diphtheria.=0D<br>=0D<br>[The full report can be fou=
nd at the above URL. - Mod.LL]=0D<br>=0D<br>--=0D<br>Communicated by:=0D<br=
>ProMED<br><br>[The following article is a good review of diphtheria:=0D<br=
>Sharma NC, Efstratiou A, Mokrousov I, Mutreja A, Das B, Ramamurthy T.<br>D=
iphtheria. Nat Rev Dis Primers. 2019 Dec 5;5(1):81. doi:<br>10.1038/s41572-=
019-0131-y.=0D<br>---------------------------------------------------------=
-----------------------=0D<br>Abstract=0D<br>--------=0D<br>"Diphtheria is =
a potentially fatal infection mostly caused by<br>toxigenic _Corynebacteriu=
m diphtheriae_ strains and occasionally by<br>toxigenic _C. ulcerans_ and _=
C. pseudotuberculosis_ strains.<br>Diphtheria is generally an acute respira=
tory infection, characterized<br>by the formation of a pseudomembrane in th=
e throat, but cutaneous<br>infections are possible. Systemic effects, such =
as myocarditis and<br>neuropathy, which are associated with increased fatal=
ity risk, are due<br>to diphtheria toxin, an exotoxin produced by the patho=
gen that<br>inhibits protein synthesis and causes cell death. Clinical diag=
nosis<br>is confirmed by the isolation and identification of the causative<=
br>_Corynebacterium_ spp., usually by bacterial culture followed by<br>enzy=
matic and toxin detection tests. Diphtheria can be treated with<br>the time=
ly administration of diphtheria antitoxin and antimicrobial<br>therapy. Alt=
hough effective vaccines are available, this disease has<br>the potential t=
o re-emerge in countries where the recommended<br>vaccination programs are =
not sustained, and increasing proportions of<br>adults are becoming suscept=
ible to diphtheria. Thousands of diphtheria<br>cases are still reported ann=
ually from several countries in Asia and<br>Africa, along with many outbrea=
ks. Changes in the epidemiology of<br>diphtheria have been reported worldwi=
de. The prevalence of toxigenic<br>_Corynebacterium_ spp. highlights the ne=
ed for proper clinical and<br>epidemiological investigations to quickly ide=
ntify and treat affected<br>individuals, along with public health measures =
to prevent and contain<br>the spread of this disease."=0D<br>=0D<br>This in=
fection is vaccine preventable in countries that have a public<br>health sy=
stem to deliver the appropriate immunogen. The toxoid for<br>diphtheria pre=
vention is now generally combined with toxoids to<br>prevent tetanus and so=
metime pertussis. Historically, the original<br>killed whole cell pertussis=
 vaccine was licensed in 1914. The same<br>year, the mixtures of diphtheria=
 toxin and antitoxin were put into<br>use. In 1926, alum-precipitated dipht=
heria toxoid was registered, and<br>in 1937 adsorbed tetanus toxoid was put=
 on the market. Pertussis<br>vaccine is now an acellullar toxoid product. -=
 Mod.LL<br><br>ProMED map:<br>Nigeria: <a href=3D"https://u19268662.ct.send=
grid.net/ss/c/sSnCkKCWBvais3EuVAOvgy2WOIX7pp1nXnn4AbwuQ3Z6WbkfhqXYXU-aTMPJ8=
yTh3CaYw13zI-QX0lLMfzql0w/435/tY0QTiX0ReqDHo3w_m7uOQ/h3/mZePPDUljWTI0PTFX7D=
M8hFAOnhTX9oaR64qyd4Zbcc">https://promedmail.org/promed-post?place=3D871434=
5,62</a>]<br><br>[See Also:<br>2023=0D<br>----=0D<br>Diphtheria - France: e=
x West Africa, multidrug resistance<br>http://promedmail.org/post/20231117.=
8713196=0D<br>Diphtheria - Asia, Africa: Pakistan (KP) South Africa (WC) fa=
tal,<br>prison http://promedmail.org/post/20231111.8713097=0D<br>Diphtheria=
 - SE Asia (06): India (HR) fatal<br>http://promedmail.org/post/20231025.87=
12821=0D<br>Diphtheria - SE Asia (04): Indonesia (JR) fatal<br>http://prome=
dmail.org/post/20230807.8711603=0D<br>Diphtheria - SE Asia (03): Indonesia =
(JI)<br>http://promedmail.org/post/20230709.8711048=0D<br>Diphtheria - Sout=
h Africa: (NL, WC) antitoxin shortage<br>http://promedmail.org/post/2023051=
9.8710144=0D<br>Diphtheria - SE Asia (02): Indonesia (JR) fatal, more cases=
, vaccine<br>campaign, RFI http://promedmail.org/post/20230319.8709034=0D<b=
r>Diphtheria - SE Asia: Indonesia, fatal, more cases, vaccine campaign,<br>=
alert http://promedmail.org/post/20230222.8708538=0D<br>2022=0D<br>----=0D<=
br>Diphtheria - France: migrants, toxigenic Corynebacterium<br>diphtheriae/=
C. ulcerans http://promedmail.org/post/20221230.8707531=0D<br>Diphtheria - =
Australia: (NSW) unvaccinated children<br>http://promedmail.org/post/202207=
05.8704239=0D<br>2018=0D<br>----=0D<br>Diphtheria - Philippines: increased =
cases, 4 regions<br>http://promedmail.org/post/20181215.6210623=0D<br>Dipht=
heria - Indonesia: fatal, more cases, vaccine campaign<br>http://promedmail=
.org/post/20180106.5542510]<br>............................................=
.....ll/may/jh<br></body>
</html><!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>*##########################################################*<br>*****=
*******************************************************<br>ProMED makes eve=
ry effort to verify the reports that are posted, but the accuracy<br>and co=
mpleteness of the information, and of any statements or opinions based<br>t=
hereon, are not guaranteed. The reader assumes all risks in using informati=
on<br>posted or archived by ProMED. ISID and its associated service provide=
rs shall not<br>be held responsible for errors or omissions or held liable =
for any damages incurred<br>as a result of use or reliance upon posted or a=
rchived material.<br>******************************************************=
******<br>Donate to ProMED. Details available at: https://isid.networkforgo=
od.com/projects/79924-invest-in-the-mission.<br>***************************=
*********************************<br>Visit ProMED's website at https://www.=
promedmail.org/.<br>Submit all items for posting via the ProMED website at =
https://promedmail.org/submitinfo/.<br>If you have any questions or need su=
pport, please contact us via the ProMED website at  https://promedmail.org/=
support/.<br>You may subscribe/unsubscribe at  https://isid.org/promedmail-=
subscribe/.<br><div><a href=3D"https://u19268662.ct.sendgrid.net/asm/?user_=
id=3D19268662&amp;data=3DNwnq9EpY-X5H7PaTmZxXTkYD4qeihjh30Myiq9yDK0hoMDAwdT=
AwMLLcgGCcfF0v9Fa2Ji6PFlm_MGEPUiVhIN37PmRW3q3PtWyOT10GRHBaf_kbDWaQBg4CI0Dt0=
o3fieBIOJ5Dr17RetC6i2F8IZ3J7-WnzEBjSdRYZRcUhHTNFojdrTIUrylzAEQxGXtvjuCh7YSG=
83-xUqQ3vyJf8mKCUQZ8cqTsOliSdbVv_wz1Yta7j-6pujigBEB-DdtChkX6C1cjSsb1U8IBmLZ=
KsKzdYRXC7UjN-xdqO29JrRyWcTKpPK7TWm809egmxI1KOwieua5TT_SfS2n3RmtqwlWUPR2csI=
qmDw4a7FkDPpUMrT31egtyUU-v5UrVBSIsX0Sbj_8r79eXOgKpZAQyBlTMf5BPKMFFY2QvFv_10=
0Jblrvb8Nku0CWAdw7EXPA90wDd9GYJtc9B87bpFSIGNK2k1zWeDTPhp3tA1YRb-406S-3yp7lg=
X02uvnj6zztDVf5hdTSUMXKOnfR1fJ46FnIe-F4CWa9pTCWGEo9XBJuXzMnZ65Nb53vuayQMxlb=
qdoyduQTEV6b4hXQh1yATAhNQ9sBq3VjV_gafy4Qe7GeHVX1VBA5uhG3lJTAxEht6xqSgomqmbG=
DrGG6Ky6aq3ONjIMVVHDk0muTV22X5SwB9sVSx9hY58lXGF3zlplBU-zI5jvjY-xqo7ORXV9gMR=
qRVCaff3F2i1sghOVX2u6O2fOnGYLmR1oqWJBlBts6G4YY7TQZrFnkl9cEWyuy__DKZktpVixd4=
D-o2_jNSEvYWk9RyXWHNVXasbHElSjrqJeoh811bwVCxYiOvNqlRBET_Se-0TCTg4DvXLQN7aAY=
LRbt5SCAlTj8AsiGSVo2--T0vgRpOVOxlfoQzinolSWv7KBkc0M9_nCqCTLKCn0JT92veDmiPzT=
iEorngQp4gBlsmxWuQNmzzbTXVHi9z7wyMq4E6L--vLBlHRa6h8Joim2X7fityc4Oc_xye0Xh4F=
QWuHHkjBZ7HSwz1Ic36QYEYDYD7T8CpycsMnF-B6FcfYbZTanscvyG150zzjgyl2eiGUVt_nOag=
-xEoS85PG0n_Ob0AyDx6qyQM-AarFIjxFTPxMfwM04psQbOauJrpVXQggUKBgNQJa4Wh70cdZ_o=
Ka_NjfCAmBRTeevGNerQVEp3SW4LB1A=3D=3D" target=3D"_blank" class=3D"Unsubscri=
be--unsubscribePreferences" style=3D"font-family:sans-serif;text-decoration=
:none;">Unsubscribe Preferences</a></div><br>##############################=
##############################<br>#########################################=
###################<br><br><img src=3D"https://u19268662.ct.sendgrid.net/ss=
/o/LbtalBvHhFtzyiegKfBhew/435/tY0QTiX0ReqDHo3w_m7uOQ/ho.gif" alt=3D"" width=
=3D"1" height=3D"1" border=3D"0" style=3D"height:1px !important;width:1px !=
important;border-width:0 !important;margin-top:0 !important;margin-bottom:0=
 !important;margin-right:0 !important;margin-left:0 !important;padding-top:=
0 !important;padding-bottom:0 !important;padding-right:0 !important;padding=
-left:0 !important;"/></body>
</html>
--f56ebc30e08713cc66201f46902592c9ace2e4c4a4088ccd62999e81c428--
